Are you Dr. Myers?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 60 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
44 Binney St
Dana Farber Cancer Institute
Boston, MA 02115Phone+1 617-632-3000- Is this information wrong?
Summary
- Dr. Andrea Myers, MD is a hematologist in Boston, Massachusetts. She is currently licensed to practice medicine in Massachusetts. She is affiliated with Dana-Farber Cancer Institute and is an Instructor in Medicine at Dana-Farber Cancer Institute.
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2007 - 2010
Massachusetts General HospitalResidency, Internal Medicine, 2005 - 2007
Stanford University School of MedicineClass of 2005
Certifications & Licensure
MA State Medical License 2007 - 2025- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Phase II, 2-Stage, 2-Arm PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer Start of enrollment: 2011 Mar 01
Publications & Presentations
PubMed
- 30 citationsPhase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancerAndrea P. Myers, Panagiotis A. Konstantinopoulos, William T. Barry, Weixiu Luo, Russell Broaddus, Vicky Makker, Ronny Drapkin, Joyce F. Liu, Austin Doyle, Neil S. Horo...> ;International Journal of Cancer. 2020 Jul 15
- 18 citationsTumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (...Andrea P. Myers, Virginia L. Filiaci, Yuping Zhang, Michael L. Pearl, Kian Behbakht, Vicky Makker, Parviz Hanjani, Susan Zweizig, James J. Burke, Gordon Downey, Kimber...> ;Gynecologic Oncology. 2016 Apr 1
- Correction: The TNF-Family Ligand TL1A and Its Receptor DR3 Promote T Cell-Mediated Allergic Immunopathology by Enhancing Differentiation and Pathogenicity of IL-9-Pro...Arianne C Richard, Cuiyan Tan, Eric T Hawley, Julio Gomez-Rodriguez, Ritobrata Goswami, Xiang-Ping Yang, Anthony C Cruz, Pallavi Penumetcha, Erika T Hayes, Martin Pell...> ;Journal of Immunology. 2015 Dec 15
- Join now to see all
Press Mentions
Cancer Fight Shows Way for U.S., China to Cool off, Collaborate: Kevin RuddAugust 16th, 2020
Study Shows Promise of Molecular Screening for Gynecologic Cancers, Commentary Writers StateJanuary 9th, 2013
Fluid from Pap Test Used to Detect Ovarian, Endometrial CancersJanuary 9th, 2013- Join now to see all
Hospital Affiliations
Dana-Farber Cancer InstituteBoston, Massachusetts
